Introduction
============

The lack of standardization for segmentation of specific volumes has been an obstacle for metabolic parameters calculation of PET images \[[@R1]--[@R5]\] especially for irregular and extensive tissue where manual segmentation is impracticable.

The use of computed tomography (CT) in hybrid nuclear medicine equipments has brought many benefits, like attenuation correction and visual correlation between functional and anatomic images \[[@R6]--[@R12]\]. Another advantage that has been explored in recent years is CT--based segmentation of PET images, where a volume of interest (VOI) is determined based on the anatomical contour and not on the patterns of radiopharmaceutical uptake \[[@R13]--[@R15]\].

For multiple myeloma, where bone involvement is an important factor for staging and clinical management of the patient \[[@R16]--[@R20]\], CT--based bone segmentation of fluorine 18 *fluorodeoxyglucose* (^18^F-FDG) PET can enable the calculation of parameters that are not yet fully explored.

In this work, we performed a CT--based skeletal segmentation of ^18^F-FDG PET images to calculate three quantitative parameters of the standardized uptake value (SUV) for bone tissue of patients with multiple myeloma: maximum (SUV~max~), mean (SUV~mean~), and standard deviation (SD) of SUV (SD~SUV~). These parameters were compared with results from visual analysis of bone involvement degree.

Method
======

This study was approved by the local ethics committee (CAAE 97966618.5.0000.5404), and written informed consent was waived by the ethics committee. We retrospectively evaluated 101 whole-body ^18^F-FDG PET/CT examinations from 58 patients with multiple myeloma according to the updated criteria of the International Myeloma Working Group (IMWG) \[[@R18]\] between 2013 and 2018. Twenty-nine of them had the ^18^F-FDG PET/CT images repeated during follow-up between June 2013 and September 2018. Therefore, 29/58 patients had one, 20/58 had two, 4/58 had three, and 5/58 had four ^18^F-FDG PET/CT performed during this period of time.

According to the standard protocol for multiple myeloma of our center, the patients were instructed to fast for at least 6 h. Image acquisitions started 60 min after the injection of 0.12 mCi/kg of ^18^F-FDG. All patients were scanned from head to feet, in a Biography mCT40 PET/CT scanner (Siemens Medical Solutions Inc., Knoxville, Tennessee, USA). The emission scan was performed in a 3D mode, 1.5 min per bed position. PET images were reconstructed using a standard iterative algorithm (ordered subset expectation maximization + point spread function + time-of-flight with 2 iterations and 21 subsets). The CT part of the study was acquired with 120--140 kV, 120 mA, transaxial field of view 700 mm, rotation time 0.8 s, and slice thickness 2.1 mm. CT data were used for attenuation correction and no correction for partial volume effect (PVE) was performed.

Prior to CT--based bone segmentation, a preprocessing was made for exclusion of external objects, like patient table and urinary catheter. Also, areas of normal ^18^F-FDG uptake (liver, bladder, kidneys, heart, and brain) were also subtracted from original PET to avoid overlapping artifacts. Internal objects in the same Hounsfield unit range as the segmented volume were not excluded unless ^18^F-FDG uptake could produce a false positive. In this case, manual exclusion was performed.

Bone segmentation was performed in four steps: (1) a CT--based segmentation using a global threshold that corresponded to the compact bone tissue to produce a masked PET image; (2) masked PET conversion to binary image; (3) morphological closing of the binary image; and (4) element-wise multiplication between closed image and original ^18^F-FDG PET image.

In the first step, we used Hounsfield unit higher than 100 as global threshold. This value was set based on CT-histogram analysis and also visual assessment. All voxels with Hounsfield unit \<100 on CT were set to zero on the correspondent masked PET.

Morphological close was made using a structuring element in a disc format with radius equal to 3 pixels. The purpose of morphological close operation was to include the 'soft' portion of the skeleton in the bone mask.

Once segmentation was completed, the following quantitative parameters were calculated exclusively for the entire bone tissue (except skull): maximum SUV (SUV~max~), mean SUV (SUV~mean~), and its respective SD (SD~SUV~). Figure [1](#F1){ref-type="fig"} shows a flowchart of this analysis.

![Flowchart for quantitative PET metrics: a CT--based segmentation, masked PET conversion to binary image, morphological closing and element-wise multiplication between closed image and original ^18^F-FDG PET image, and finally, quantitative metrics calculation. CT, Computed tomography; ^18^F-FDG PET, fluorine 18 fluorodeoxyglucose PET.](nmc-41-377-g001){#F1}

CT--based segmentation was performed using the Beth Israel Plugin for Fiji \[[@R21],[@R22]\]. Final bone mask and quantitative metrics calculations were performed with an in-house software implemented in MATLAB, Natick, Massachusetts, USA \[[@R23],[@R24]\].

Global visual analysis of ^18^F-FDG PET/CT was performed by two experienced nuclear physicians. They classified images as negative when no focal lesion or diffuse disease was found on ^18^F-FDG PET/CT examinations. Mild bone involvement was defined when less than five focal lesions or limited/mild diffuse disease was observed on image. Images were classified as moderate bone involvement when 5--20 focal lesions or moderate diffuse disease was observed. Images were classified as presenting marked bone involvement when more than 20 focal lesions or severe diffuse disease was observed \[[@R25],[@R26]\].

We applied the generalized estimating equation (GEE) to the univariate analysis to verify the relation between quantitative parameters and the global visual analysis \[[@R27]\]. Univariate analysis was performed by using the Statistical Analysis *Software* for Windows (SAS Institute Inc, 2002--2008, Cary, North Carolina, USA).

Results
=======

The visual analysis classified 45 of the 101 ^18^F-FDG PET/CT images (44.5%) as negative or presenting mild bone involvement, 32 (31.7%) as moderate and 24 (23.8%) as marked bone involvement (Fig. [2](#F2){ref-type="fig"}).

![Limitation of maximum SUV (SUV~max~) as compared with mean SUV (SUVmean) and its SD (SD~SUV~) for evaluating bone involvement in multiple myeloma SUV~mean~. (a), (b), and (c) correspond to patients visually classified as presenting mild, moderate, and marked bone involvement, respectively. Their correspondent SUV~max~, SUV~mean~, and SD~SUV~ are shown. The point with the highest SUV in each patient is, respectively, the sternum, right shoulder, and clavicle for (a), (b), and (c). Note that, in opposition to SUV~mean~ and SD~SUV~, SUV~max~ was not able to express the progressive intensity of bone involvement from (a) to (c), as defined by visual analysis. Also note that the proposed method evaluates only the osseous portion of the lesions and does not account for extraosseous extension of the disease, as seen in the left shoulder of the patient in (b). SUV, standardized uptake values; SUV~max~, maximum SUV; SUV~mean~, mean SUV; SDsuv, standard deviation of SUV.](nmc-41-377-g002){#F2}

Mean SUV~max~, mean SUV~mean~, and mean SD~SUV~ were, respectively: 8.5 ± 6.6, 0.9 ± 0.1, and 0.5 ± 0.1 for images classified as negative or mild bone involvement; 12.8 ± 7.8, 0.9 ± 0.1, and 0.7 ± 0.1 for moderate bone involvement; and 27.8 ± 36.4, 1.2 ± 0.2, and 1.1 ± 0.4 for marked bone involvement (Fig. [3](#F3){ref-type="fig"}). Univariate statistical analysis using GEE showed that all quantitative parameters for bone tissue were significantly related to visual assessment by nuclear physicians (*P* \< 0.05). The odds ratio (OR) for SUV~max~ was 1.01 \[(95% confidence interval (CI), 1.003--1.022)\]; for SUV~mean~ OR, 10.52 (95% CI, 5.68--19.48); and for SD~SUV~ OR, 5.58 (95% CI, 3.31--9.42).

![Box plot comparing the three categories of visual assessment of bone involvement for quantitative PET metrics for maximum SUV of bone tissue, mean SUV and SD of SUV. SUV, standardized uptake values.](nmc-41-377-g003){#F3}

All mean quantitative parameters for each category, its respective ranges, and results for statistic analysis are described in Table [1](#T1){ref-type="table"}.

###### 

Quantitative parameters of PET/computed tomography for patients with multiple myeloma classified into three groups
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Discussion
==========

Bone imaging, especially ^18^FDG PET-CT, has become a mainstay in diagnostic evaluation of multiple myeloma \[[@R28]--[@R30]\]. Besides, it has been used for measuring treatment response and as an important prognostic factor in this disease. However, quantification of bone disease in multiple myeloma has not been fully standardized, and often semiquantitative measures have been used. Several efforts have been made in order to standardize an objective quantitative measure that can be widely reproducible. SUV~max~ has been widely used for many purposes \[[@R28],[@R29],[@R31]\]. The study by Sager *et al*. \[[@R29]\] on bone involvement at initial staging of patients with multiple myeloma found a significant correlation between SUV~max~ and bone marrow cellularity and percentage of plasma cells. Using a multivariate analysis, Zamagni *et al*. \[[@R28]\] found that persistent SUV~max~ above 4.2 after first-line treatment was independently associated with disease progression. Bailly *et al*. \[[@R31]\] proposed SUV~max~ reduction (ΔSUV~max~) as a powerful tool for the prediction of long-term outcome in patients with FDG-avid multiple myeloma.

On the other hand, the intrinsic limitation of analyzing SUV~max~ as a single voxel with largest intensity is well known and it is evident in Fig. [2](#F2){ref-type="fig"}. Segmenting only both femurs, Ak and Gulbas \[[@R30]\] calculated the SUV~mean~ of patients with multiple myeloma and found that they were negatively correlated with serum albumin levels of the patients. The CT--based segmentation of the whole skeleton described here may allow a routine use of SUV~mean~ and SD~SUV~, being reproducible and more robust than SUV~max~. These parameters could be used to compare different patients and treatments and to access patients' outcome.

Some studies have reported evaluation of the metabolic activity of bone tissue using total or partial segmentation of the skeleton \[[@R32]--[@R35]\]. Leydon *et al*. \[[@R32]\] calculated SUV~mean~ in specific regions such as femur, iliac crest, lumbar spine, and sternum for patients with and without chemotherapy, using a CT--based segmentation as one of the steps of image analysis. Nguyen *et al.* \[[@R33]\] also made partial segmentation of the skeleton to assess hematopoietic tissue proliferation on the corresponding vertebral body volume on PET. Mean and maximum SUVs for L1, L3, and L5 of lumbar spine were calculated by Basu *et al*. \[[@R35]\] for five patients with negative FDG PET/CT using MRI-based segmentation. Partial and total skeleton segmentation was executed by Sambuceti *et al*. \[[@R34]\] to measure the metabolic activity of the bone marrow on FDG PET/CT, and they found a mean SUV of intraosseous space equal to 0.96 ± 0.17 for 35 patients with nonmetastatic melanoma.

Differently from the studies mentioned above, in the present study, we correlated quantitative parameters for whole skeleton with clinical evaluation of the image. We used CT--based segmentation as a tool to calculate three quantitative parameters exclusively for the entire bone tissue for patients with multiple myeloma: SUV~max~, SUV~mean~, and SD~SUV~. Interestingly, SUV~mean~ was the parameter that correlated best with the visual analysis, followed by the SD~SUV~. This feature can give a good measure of the overall bone involvement in multiple myeloma. Both are first-order texture parameters \[[@R36]\], and in this specific case, they cannot be obtained without bone segmentation.

An important limitation of our method is the need to exclude patient's skull. Normal ^18^F-FDG brain uptake causes artifacts, generated as 'false-positive' areas of skull uptake. The same limitation was described by Sambuceti *et al*. \[[@R34]\]. Another expected limitation of the approach proposed in the present study is that information about extramedullary lesions or soft tissue involvement is neglected and should be evaluated separately. This also occurs with lesions that exceed the bone limits, since the mathematical index represents only the osseous portion of the lesions.

It is possible that the quantitative parameters studied here may be greatly influenced by PVE, which is known to be an important factor in PET quantification. However, the application of PVE correction in ^18^F-FDG PET/CT is not yet established, especially for nonbrain studies. Also, PVE correction is unavailable in commercial systems \[[@R37]--[@R40]\].

Some artifacts intrinsic of CT--based segmentation may affect quantitative PET imaging parameters as well as bone contour and need special attention, such as metal implants, urinary catheter, and normal 'nonbone' ^18^F-FDG uptake overlapping the segmented VOI \[[@R41]\]. In these cases, manual subtraction or manual correction of these artifacts should be performed.

Conclusion
----------

CT-based skeletal segmentation can be used to calculate reproducible quantitative parameters for patients with multiple myeloma. Using this method, SUV~mean~ and its respective SD correlated better with the visual analysis of ^18^F-FDG-PET images than SUV~max~.
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